Asset 2 Conferences
Alimonti Andrea - VIB Training & Conferences - Speaker picture

Andrea Alimonti

Università della Svizzera italiana; Institute of Oncology Research, CH
Biography

Andrea Alimonti is Director of the Institute of Oncology Research (IOR) in Bellinzona, Switzerland, and Full Professor of Experimental Oncology and Translational Cancer Medicine at ETH Zurich, Oncology at Università della Svizzera italiana, and Pharmacology at the University of Padua. He also heads the Molecular Oncology research program at IOR. Previously, he conducted postdoctoral research at Memorial Sloan Kettering Cancer Center and Harvard Medical School in the United States.

His research focuses on prostate cancer, cellular senescence, tumor immunology, and therapeutic resistance. His pioneering studies demonstrated the role of PTEN dosage in tumorigenesis and established the concept of pro-senescence therapy for cancer. He has also made fundamental contributions to understanding how immunosuppressive myeloid cells promote prostate cancer progression and treatment resistance. More recently, his team has uncovered mechanisms linking gut microbiota, senescence, and the tumor immune microenvironment to therapeutic resistance. His work also extends to senotherapeutic approaches for healthy aging. Collectively, his research has led to the development of innovative therapeutic strategies and the initiation of clinical trials.

Andrea Alimonti has received numerous prestigious awards, including the Swiss Bridge Award, Joseph Steiner Award, Robert Wenner Prize, Cloëtta Prize, and two Prostate Cancer Foundation Challenge Awards. He has secured three European Research Council grants (Starting, Consolidator, and Advanced) and serves on several national and international scientific advisory boards. He is also actively involved in teaching and PhD supervision at leading academic institutions.

Speaker at